Correlation of histologic regression in primary melanoma with sentinel node status

JAMA Dermatology

Volumn 150, Issue 8, 2014, Pages 828-835

  Botella Estrada, Rafael ^a,b   Traves, Victor ^a   Requena, Celia ^a   Guillen Barona, Carlos ^a   Nagore, Eduardo ^a  

^a INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

^b HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

PARAFFIN;

ADULT; AGED; ARTICLE; DERMATOLOGY; FEMALE; HISTOLOGY; HOSPITAL; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MALIGNANT LENTIGO; MELANOMA; MIDDLE AGED; PRIMARY TUMOR; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENTINEL LYMPH NODE BIOPSY; SENTINEL LYMPH NODE METASTASIS; YOUNG ADULT;

ADULT; EXTREMITIES; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; HUTCHINSON'S MELANOTIC FRECKLE; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM REGRESSION, SPONTANEOUS; RETROSPECTIVE STUDIES; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS; TORSO;

EID: 84906773155     PISSN: 21686068     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamadermatol.2013.9856     Document Type: Article

References (26)

1. Blessing K, McLaren KM. Histological regression in primary cutaneous melanoma: recognition, prevalence and significance. Histopathology. 1992;20(4):315-322.
2. Requena C, Botella-Estrada R, Traves V, Nagore E, Almenar S, Guillén C. Problems in defining melanoma regression and prognostic implication [in Spanish]. Actas Dermosifiliogr. 2009;100(9):759-766.
3. Gromet MA, Epstein WL, Blois MS. The regressing thin malignant melanoma: a distinctive lesion with metastatic potential. Cancer. 1978;42(5):2282-2292. (Pubitemid 9125886)
4. Guitart J, Lowe L, Piepkorn M, et al. Histological characteristics of metastasizing thin melanomas: a case-control study of 43 cases. Arch Dermatol. 2002;138(5):603-608.
5. Slingluff CL Jr, Seigler HF. "Thin" malignant melanoma: risk factors and clinical management. Ann Plast Surg. 1992;28(1):89-94.
6. Ronan SG, Eng AM, Briele HA, Shioura NN, Das Gupta TK. Thin malignant melanomas with regression and metastases. Arch Dermatol. 1987;123(10):1326-1330. (Pubitemid 17152295)
7. Clark WH Jr, Elder DE, Guerry D IV, et al. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst. 1989;81(24):1893-1904. (Pubitemid 20026075)
8. Blessing K, McLaren KM, McLean A, Davidson P. Thin malignant melanomas (less than 1.5 mm) with metastasis: a histological study and survival analysis. Histopathology. 1990;17(5):389-395.
9. Kelly JW, Sagebiel RW, Blois MS. Regression in malignant melanoma: a histologic feature without independent prognostic significance. Cancer. 1985;56(9):2287-2291. (Pubitemid 16236607)
10. McGovern VJ, Shaw HM, Milton GW. Prognosis in patients with thin malignant melanoma: influence of regression. Histopathology. 1983;7(5):673-680. (Pubitemid 13048183)
11. Brogelli L, Reali UM, Moretti S, Urso C. The prognostic significance of histologic regression in cutaneous melanoma. Melanoma Res. 1992;2(2):87-91.
12. Morris KT, Busam KJ, Bero S, Patel A, Brady MS. Primary cutaneous melanoma with regression does not require a lower threshold for sentinel lymph node biopsy. Ann Surg Oncol. 2008;15(1):316-322.
13. Burton AL, Gilbert J, Farmer RW, et al. Regression does not predict nodal metastasis or survival in patients with cutaneous melanoma. Am Surg. 2011;77(8):1009-1013.
14. Ribero S, Osella-Abate S, Sanlorenzo M, et al. Favourable prognostic role of regression of primary melanoma in stage I-II AJCC patients. Br J Dermatol. 2013;169(6):1240-1245.
15. Oláh J, Gyulai R, Korom I, Varga E, Dobozy A. Tumour regression predicts higher risk of sentinel node involvement in thin cutaneous melanomas. Br J Dermatol. 2003;149(3):662-663. (Pubitemid 37281612)
16. Tefany FJ, Barnetson RS, Halliday GM, McCarthy SW, McCarthy WH. Immunocytochemical analysis of the cellular infiltrate in primary regressing and non-regressing malignant melanoma. J Invest Dermatol. 1991;97(2):197-202.
17. Fontaine D, Parkhill W, Greer W, Walsh N. Partial regression of primary cutaneous melanoma: is there an association with sub-clinical sentinel lymph node metastasis? Am J Dermatopathol. 2003;25(5):371-376. (Pubitemid 37169464)
18. Kaur C, Thomas RJ, Desai N, et al. The correlation of regression in primary melanoma with sentinel lymph node status. J Clin Pathol. 2008;61(3):297-300. (Pubitemid 351354233)
19. Nagore E, Botella-Estrada R, Requena C, et al. Clinical and epidemiologic profile of melanoma patients according to sun exposure of the tumor site [in Spanish]. Actas Dermosifiliogr. 2009;100(3):205-211.
20. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27(36):6199-6206.
21. American Joint Committee on Cancer. Manual for Staging of Cancer. 3rd ed. Philadelphia, PA: JB Lippincott Co; 1988.
22. Cook MG. The significance of inflammation and regression in melanoma. Virchows Arch A Pathol Anat Histopathol. 1992;420(2):113-115.
23. Kang S, Barnhill RL, Mihm MC Jr, Sober AJ. Histologic regression in malignant melanoma: an interobserver concordance study. J Cutan Pathol. 1993;20(2):126-129. (Pubitemid 23215561)
24. Massi G, LeBoit P. Histological Diagnosis of Nevi and Melanoma. Darmstadt, Germany: Steinkopff Verlag; 2004.
25. Trau H, Kopf AW, Rigel DS, et al. Regression in malignant melanoma. J Am Acad Dermatol. 1983;8(3):363-368. (Pubitemid 13147753)
26. Bastian BC. Hypothesis: a role for telomere crisis in spontaneous regression of melanoma. Arch Dermatol. 2003;139(5):667-668. (Pubitemid 36576389)